Compiled here, all relevant comments and discussions regarding the SRPT stock. Please note that all comments included here have met Investing.com's Comment Guidelines.
What is your sentiment on Sarepta?
or
Market is currently closed. Voting is open during market hours.
All Comments
(59)
120+ very soon
7
Huge Discount BUY BUY BUY!!!
3
Good timing
0
Target is 82$
2
this company is trash
0
On the 19th you said it will hit 100s, make up your mind
0
it will but looks like it will take 3 months. But I added 100 lots more.
0
I was hopeful it would bounce from the over reaction, bought at $91 after the dip...playing the long game now, but painful right now
0
Going big.
0
market is ********up right now. just wait couple months and it will hit 100s
0
Sell on the news
0
link?
0
115 !!!
0
Buy. Target 115-120$
0
arkg buy yesterday
0
The Food and Drug Administration is scheduled to rule on Sarepta Therapeutics Inc's (NASDAQ: SRPT) new drug application for casimersen, a treatment for patients with Duchenne muscular dystrophy who have certain genetic mutations. The PDUFA goal date is Thursday, Feb. 25.
0
CAMBRIDGE, Mass., Feb. 22, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, will report fourth quarter and full-year 2020 financial results after the Nasdaq Global Market closes on Monday, March 1, 2021. Subsequently, at 4:30 p.m. E.T., the Company will host a conference call to discuss its fourth quarter and full year 2020 financial results and to provide a corporate update.
0
Qwerty
0
Letsgoo
0
CAMBRIDGE, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) -- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, granted equity awards on January 29, 2021 that were previously approved by the Compensation Committee of its Board of Directors under Sarepta’s 2014 Employment Commencement Incentive Plan, as a material inducement to employment to 26 individuals hired by Sarepta in January 2021. The equity awards were approved in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received, in the aggregate, options to purchase 20,565 shares of Sarepta's common stock, and in the aggregate, 7,760 restricted stock units (“RSUs”). The options have an exercise price of $89.40 per share, which is equal to the closing price of Sarepta's common stock on January 29, 2021 (the “Grant Date”). One-fourth of the shares underlying each employee’s option will vest on the one-year anniversary of the Grant Date and thereafter 1/48th of the shares underlyi
0
about to take off... all aboard
0
2.7 million pump
0
sarepta is going back to the sky
2
pre-market is good, planning to rich TP on 208 this week
1
should be resistance at 208
1
Alex Bugaj can you explain resistance at 208. Why would you say that?
0
In Singh on 1h chart draw support & resistance levels starting from 08.01.21. It'll show what tomorrow after the market open need to TP if you are going short (it'll be about ± $104.5 per share)
0
this is will go back to his hight. with earning coming, it should break 100 easily soon